Pharmacometabolomic Profiling Of The General Population: Relation Of Active Metabolite Levels To Cardiovascular Risk Factor Control And Manifest Atherosclerosis
(2021) American Heart Association (AHA), Scientific Session 2021 In Circulation 144(suppl_1).- Abstract
- Introduction: The use of medications in the general population has increased over time. Information on active metabolite concentrations for common drugs in the general population is limited. Recent advances in metabolomic technologies have made high-throughput profiling of many active metabolites in large epidemiological cohorts increasingly feasible.
Aim: 1. Prospective assessment of the proportion of measurable active metabolite levels of major drugs in the general population using mass spectrometry. 2. Relation of cardiovascular (CV) drugs with inadequate risk factor control and CV disease.
Methods: Assessment of CV risk factors by coronary CT angiography and carotid ultrasound imaging in a large prospective cohort of... (More) - Introduction: The use of medications in the general population has increased over time. Information on active metabolite concentrations for common drugs in the general population is limited. Recent advances in metabolomic technologies have made high-throughput profiling of many active metabolites in large epidemiological cohorts increasingly feasible.
Aim: 1. Prospective assessment of the proportion of measurable active metabolite levels of major drugs in the general population using mass spectrometry. 2. Relation of cardiovascular (CV) drugs with inadequate risk factor control and CV disease.
Methods: Assessment of CV risk factors by coronary CT angiography and carotid ultrasound imaging in a large prospective cohort of 6,251 individuals randomly selected from the general population in Malmö, Sweden (age 50-64 years). Untargeted metabolomic profiling of fasting plasma was performed by Metabolon, USA in a random subset of 3,986 subjects.
Results: Intake of at least one prescribed drug was reported in 1840 subjects (46%). Combination drugs were reported in 249 subjects (6%). The most common drug classes reported were lipid-lowering (n=369, 9% of which most were statins), beta blockers (n=307, 8%), ARB (n=272, 7%), and ACE inhibitors (268, 7%), followed by levothyroxine, CCB, antidepressants, glucocorticoids, PPI, antidiabetic, bronchodilators and diuretics. For major CV drugs, detectable active metabolite levels ranged from 54% (atorvastatin and enalapril) to 96% (metoprolol and metformin). Non-detectable levels of lipid-lowering, antihypertensive, and antidiabetic drugs were associated with higher LDL, cholesterol, BP and glucose, although only antidiabetic drugs were significant (p<0.05). Non-detectable levels of lipid-lowering and antihypertensive drugs were also non-significantly associated with increased coronary calcium and carotid plaque.
Conclusion: Our study provides an overview of the distribution of common drugs with detectable levels in a contemporary Swedish population. Pharmacometabolomic profiling revealed that non-measurable levels of common CV drugs were associated with lower risk factor control and non-significant trends towards more atherosclerotic disease by imaging in a substantial number of subjects. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5df6e346-1d58-4a66-9f32-d2d6b776755d
- author
- Johansson, Madeleine
LU
; Ghosh, Nilanjan ; Lejonberg, Carl LU ; Czuba, Tomasz LU ; Landenhed Smith, Maya LU ; Fall, Tove ; Engström, Gunnar LU and Smith, Gustav LU
- organization
-
- Cardiovascular Research - Hypertension (research group)
- Molecular Epidemiology and Cardiology (research group)
- Cardiology
- EXODIAB: Excellence of Diabetes Research in Sweden
- Artificial Intelligence in CardioThoracic Sciences (AICTS) (research group)
- Thoracic Surgery
- Cardiovascular Research - Epidemiology (research group)
- EpiHealth: Epidemiology for Health
- WCMM-Wallenberg Centre for Molecular Medicine
- Heart Failure and Mechanical Support (research group)
- Cardiovascular Epigenetics (research group)
- publishing date
- 2021-11-08
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cardiology, Metabolomics, EPIDEMIOLOGY, Atherosclerosis, Cardiovascular risk factors
- in
- Circulation
- volume
- 144
- issue
- suppl_1
- article number
- A14097
- publisher
- Lippincott Williams & Wilkins
- conference name
- American Heart Association (AHA), Scientific Session 2021
- conference location
- Boston, United States
- conference dates
- 2021-11-13 - 2021-11-15
- ISSN
- 1524-4539
- language
- English
- LU publication?
- yes
- id
- 5df6e346-1d58-4a66-9f32-d2d6b776755d
- alternative location
- https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.14097
- date added to LUP
- 2021-11-20 17:42:51
- date last changed
- 2021-11-23 02:28:49
@misc{5df6e346-1d58-4a66-9f32-d2d6b776755d, abstract = {{Introduction: The use of medications in the general population has increased over time. Information on active metabolite concentrations for common drugs in the general population is limited. Recent advances in metabolomic technologies have made high-throughput profiling of many active metabolites in large epidemiological cohorts increasingly feasible.<br/><br/>Aim: 1. Prospective assessment of the proportion of measurable active metabolite levels of major drugs in the general population using mass spectrometry. 2. Relation of cardiovascular (CV) drugs with inadequate risk factor control and CV disease.<br/><br/>Methods: Assessment of CV risk factors by coronary CT angiography and carotid ultrasound imaging in a large prospective cohort of 6,251 individuals randomly selected from the general population in Malmö, Sweden (age 50-64 years). Untargeted metabolomic profiling of fasting plasma was performed by Metabolon, USA in a random subset of 3,986 subjects.<br/><br/>Results: Intake of at least one prescribed drug was reported in 1840 subjects (46%). Combination drugs were reported in 249 subjects (6%). The most common drug classes reported were lipid-lowering (n=369, 9% of which most were statins), beta blockers (n=307, 8%), ARB (n=272, 7%), and ACE inhibitors (268, 7%), followed by levothyroxine, CCB, antidepressants, glucocorticoids, PPI, antidiabetic, bronchodilators and diuretics. For major CV drugs, detectable active metabolite levels ranged from 54% (atorvastatin and enalapril) to 96% (metoprolol and metformin). Non-detectable levels of lipid-lowering, antihypertensive, and antidiabetic drugs were associated with higher LDL, cholesterol, BP and glucose, although only antidiabetic drugs were significant (p<0.05). Non-detectable levels of lipid-lowering and antihypertensive drugs were also non-significantly associated with increased coronary calcium and carotid plaque.<br/><br/>Conclusion: Our study provides an overview of the distribution of common drugs with detectable levels in a contemporary Swedish population. Pharmacometabolomic profiling revealed that non-measurable levels of common CV drugs were associated with lower risk factor control and non-significant trends towards more atherosclerotic disease by imaging in a substantial number of subjects.}}, author = {{Johansson, Madeleine and Ghosh, Nilanjan and Lejonberg, Carl and Czuba, Tomasz and Landenhed Smith, Maya and Fall, Tove and Engström, Gunnar and Smith, Gustav}}, issn = {{1524-4539}}, keywords = {{Cardiology; Metabolomics; EPIDEMIOLOGY; Atherosclerosis; Cardiovascular risk factors}}, language = {{eng}}, month = {{11}}, note = {{Conference Abstract}}, number = {{suppl_1}}, publisher = {{Lippincott Williams & Wilkins}}, series = {{Circulation}}, title = {{Pharmacometabolomic Profiling Of The General Population: Relation Of Active Metabolite Levels To Cardiovascular Risk Factor Control And Manifest Atherosclerosis}}, url = {{https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.14097}}, volume = {{144}}, year = {{2021}}, }